[ Indi Molecular raises $11.5M in Series A funding ]
Indi Molecular has raised $11.5 million in Series A funding.
Founded in 2013, Indi Molecular is an emerging life sciences company that is developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents ( PCC).
The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.
|City||Culver City, California|
|Founder / CEO||Albert A. Luderer|
|Asset Management Ventures (AMV)|
|Previous Investors||Asset Management Ventures (AMV)|